Type 2 immunity in asthma

 
Marco Caminati, Duy Le Pham, Diego Bagnasco and Giorgio Walter Canonica
 
World Allergy Organization Journal 2018 11:13

https://doi.org/10.1186/s40413-018-0192-5

Abstract

Type 2-immunity represents the typical adaptive response to allergen exposure in atopic individuals. It mainly involves Th2 cells and immunoglobulin E, as the main orchestrators of type 2-inflammation. Recently, it has been highlighted that allergens may be responsible for a Th2 response beside specific IgE activation and that a number of other environmental stimuli, such as viruses and pollutants, can trigger the same pattern of inflammation beyond atopy. Emerging data sustain a substantial role of the so-called epithelial dysfunction in asthma pathogenesis, both from anatomic and functional point of view. Furthermore an increasing amount of evidence demonstrates the relevance of innate immunity in polarizing a Th2 impaired response in asthmatic patients. Under this perspective, the complex cross-talking between airway epithelium, innate and adaptive immunity is emerging as a major determinant of type 2-inflammation beyond allergens.

This review will include an update on the relevance of dysregulation of innate and adaptive type 2-immunity in asthma pathogenesis, particularly severe asthma, and on the role of the allergens that are associated with severe asthma. Type 2-immunity also will be reviewed in the light of the current and upcoming targeted treatments for severe asthma.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Weekly Clinical Case Challenge from Derm101. What is your diagnosis? https://t.co/MKRIih9ePL https://t.co/tfv97WusKJ
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: WORLD ALLERGY CONGRESS | WAC2019 - WORLD ALLERGY CONGRESS https://t.co/LR5vgHROK7, see more https://t.co/jgCeENQuZt
1hreplyretweetfavorite
Interasma RT @Aller_MD: “Global Temperature Affects Dengue” https://t.co/ICMfeeMBIj
1hreplyretweetfavorite
Interasma RT @Aller_MD: “The Risks and Benefits of Expedited Drug Reviews. The US Food and Drug Administration (FDA) oversees several programs that e…
1hreplyretweetfavorite
Interasma RT @Aller_MD: “Health Data and Privacy in the Digital Era” https://t.co/Q3bND39qKb https://t.co/VXukVQi7B7
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma